In recent years, 3D printing has made leaps and bounds in the fields of medicine and biotechnology. Developments such as 3D printed prosthetic limbs have made headlines quite frequently, but news about bioprinting is not often seen because 3D printed biological tissues and organs layered by living cells are highly complex and expensive to manufacture. According to 3D Tiger, AspectBiosystems is a Canadian biotechnology company and is a leader in bioprinting and tissue engineering. Yesterday, Aspect announced a partnership with healthcare specialist DePuySynthes Products, promising to conduct research on bioprinting in a completely new way. The collaboration is promoted by DePuy ’s parent company and pharmaceutical giant Johnson & Johnson, and will see Aspect Lab ’s bioprinters being used to develop bioprintable knee menisci suitable for surgical treatment. For those unfamiliar, the meniscus is a type of cartilage that provides a cushion between the thigh bone and the tibia, similar to a knee “shock absorberâ€. The meniscus tear is one of the most common knee injuries, and the incidence may increase gradually as the population ages. Surgical treatment of a torn meniscus may involve partial or complete removal, which is related to the incidence of osteoarthritis. In order to solve this problem, Aspect and DePuy will use Aspect's bio-printer Lab-on-a-Printer to develop an artificial meniscus prototype, which is an important step for postoperative patients. AspectBiosystems President and CEO TamerMohamed said: "We are very pleased to work with global healthcare leaders like DePuySynthes. This collaboration marks Aspect will make an important progress in this field, using our biological 3D printing technology development Breakthrough tissue replacement therapy to improve patients' quality of life. " As for the new agreement between Depuy and Aspect, Johnson & Johnson will have more than 300 partnerships since its establishment. "We continue to seek transformative healthcare solutions and form partnerships to explore the forefront of scientific research to achieve our main goals and improve the quality of life for patients," said Paul Stoffels, Johnson & Johnson's Chief Scientific Officer. "Through Johnson & Johnson's innovation, we are committed to identifying and advancing new solutions in major demand areas, and working with innovators to create customized transaction structures to accelerate product launches." As the bioprinting collaboration between the two companies moves forward, it is only a matter of time before other 3D printing and biotechnology research solutions emerge. Editor in charge: Liu Qingqing Ningbo Wellcome Trading Co., Ltd. , https://www.huike-homecare.com
